» Articles » PMID: 33494708

Neuromyelitis Optica Spectrum Disorders with Non Opticospinal Manifestations As Initial Symptoms: a Long-term Observational Study

Overview
Journal BMC Neurol
Publisher Biomed Central
Specialty Neurology
Date 2021 Jan 26
PMID 33494708
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Early stage neuromyelitis optica spectrum disorders (NMOSD) with non-opticospinal manifestations as initial symptoms are easily misdiagnosed; however, data on the full symptom profile are limited. Moreover, the clinical characteristics and long-term outcomes of these patients remain unknown. We sought to analyze the clinical characteristics, imaging features, and long-term outcomes of NMOSD with non-opticospinal manifestations as initial symptoms.

Methods: We retrospectively included relevant patients from our center. Clinical, demographic, magnetic resonance imaging, treatment, and outcome data were compared according to the non-opticospinal vs. opticospinal initial symptoms.

Results: We identified 43 (9.13 %) patients with non-opticospinal initial symptoms among 471 patients with NMOSD. Of these, 88.37 % developed optic neuritis/myelitis during an average follow-up period of 6.33 years. All the non-opticospinal symptoms were brain/brainstem symptoms. Most of the symptoms and associated brain lesions were reversible. These patients had a younger onset age (P < 0.001), lower serum aquaporin-4 (AQP4) antibody titers (P = 0.030), and a lower Expanded Disability Status Scale (EDSS) score at onset (P < 0.001) and follow-up (P = 0.041) than NMOSD patients with opticospinal initial symptoms. In addition, EDSS scores reached 3.0 (indicating moderate disability) later than in patients with opticospinal initial symptoms (P = 0.028).

Conclusions: Patients with NMOSD with non-opticospinal initial symptoms have a younger onset age, lower serum AQP4 antibody titers, and better clinical outcomes.

Citing Articles

Neuromyelitis optica spectrum disorder with acute brainstem manifestations as initial symptoms.

Li Z, Yang M, Pan Y, Fang Q Heliyon. 2024; 10(12):e32539.

PMID: 38988536 PMC: 11233896. DOI: 10.1016/j.heliyon.2024.e32539.


Update on the diagnosis and treatment of neuromyelits optica spectrum disorders (NMOSD) - revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part I: Diagnosis and differential diagnosis.

Jarius S, Aktas O, Ayzenberg I, Bellmann-Strobl J, Berthele A, Giglhuber K J Neurol. 2023; 270(7):3341-3368.

PMID: 37022481 PMC: 10267280. DOI: 10.1007/s00415-023-11634-0.

References
1.
Duvernoy H, Risold P . The circumventricular organs: an atlas of comparative anatomy and vascularization. Brain Res Rev. 2007; 56(1):119-47. DOI: 10.1016/j.brainresrev.2007.06.002. View

2.
Wingerchuk D, Banwell B, Bennett J, Cabre P, Carroll W, Chitnis T . International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015; 85(2):177-89. PMC: 4515040. DOI: 10.1212/WNL.0000000000001729. View

3.
Roemer S, Parisi J, Lennon V, Benarroch E, Lassmann H, Bruck W . Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis. Brain. 2007; 130(Pt 5):1194-205. DOI: 10.1093/brain/awl371. View

4.
Lennon V, Wingerchuk D, Kryzer T, Pittock S, Lucchinetti C, Fujihara K . A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet. 2004; 364(9451):2106-12. DOI: 10.1016/S0140-6736(04)17551-X. View

5.
Kleiter I, Gahlen A, Borisow N, Fischer K, Wernecke K, Wegner B . Neuromyelitis optica: Evaluation of 871 attacks and 1,153 treatment courses. Ann Neurol. 2015; 79(2):206-16. DOI: 10.1002/ana.24554. View